Join our daily newsletter At The Bell to receive exclusive market insights
- Medibio (MEB) has signed its first statement of works agreement with Compass Group Plc to begin implementation of its corporate mental health software in the U.K.
- The software, called Ilumen, gives employers and employees a snapshot of their mental wellbeing to make improvements over time
- The agreement marks the first stage of the Ilumen roll out to the Compass UK workforce, which allows up to one thousand employees to participate for a minimum period of 12 months
- Medibio is in the grey, last trading at 0.9 cents
Medibio (MEB) has signed its first statement of works agreement with Compass Group Plc to begin implementation of Ilumen in the U.K.
Ilumen, a corporate mental health software product, gives employers aggregated data to measure and manage the wellbeing of its workforce, while providing the employee with a mental wellbeing “snapshot” to allow them to make improvements over time.
Employees identified as high-risk will then receive a confidential, personalised notification.
Medibio and Compass Group entered into a global master service agreement in November 2020 to establish a framework for the implementation of Ilumen by Compass’ subsidiaries.
The subsidiaries can implement Ilumen by simply agreeing to a statement of works, which details the number of employees eligible to participate. All other material terms of implementation will be outlines in the master agreement.
The agreement marks the first stage of the Ilumen roll out to the Compass UK workforce, which allows up to one thousand employees to participate for a minimum period of 12 months.
“We are delighted to begin the implementation of Ilumen with Compass UK,” said Medibio SVP of Corporate Health, Jennifer Solitario.
“Compass is a priority, and our discussions with subsidiaries have been progressing nicely, so it is especially rewarding to solidify this arrangement with Compass UK. These companies will act as an excellent reference point as we expand our global outlook for Ilumen.”
Medibio is in the grey, last trading at 0.9 cents at 9:45 am AEDT.
